Overview

Feasibility And Safety Study Of rhBMP-2/CPM For Hip Fractures

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the safety of administering rhBMP-2/CPM as an adjuvant to internal fixation in subjects with fractures of the proximal femur.
Phase:
Phase 2
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer